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KidneyMachine Learning to Identify Dialysis
Patients at High Death Risk
Oguz Akbilgic1,2, Yoshitsugu Obi3, Praveen K. Potukuchi4, Ibrahim Karabayir1,5,
Danh V. Nguyen6, Melissa Soohoo3, Elani Streja3, Miklos Z. Molnar4,7,8,9, Connie M. Rhee3,
Kamyar Kalantar-Zadeh3 and Csaba P. Kovesdy4
1Center for Biomedical Informatics, Department of Pediatrics, University of Tennessee Health Science Center, Memphis,
Tennessee, USA; 2Department of Health Informatics and Data Science, Parkinson School of Health Sciences and Public Health,
Loyola University Chicago, Maywood, Illinois, USA; 3Harold Simmons Center for Kidney Disease Research and Epidemiology,
Division of Nephrology and Hypertension, University of California Irvine Medical Center, Orange, California, USA; 4Division of
Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, Tennessee, USA; 5Faculty of
Economics and Administrative Sciences, Kirklareli University, Kirklareli, Turkey; 6Division of General Internal Medicine, Uni-
versity of California Irvine Medical Center, Orange, California, USA; 7Department of Surgery, Methodist University Hospital
Transplant Institute, Memphis, Tennessee, USA; 8Division of Transplant Surgery, Department of Surgery, University of Ten-
nessee Health Science Center, Memphis, Tennessee, USA; and 9Department of Transplantation and Surgery, Semmelweis
University, Budapest, HungaryIntroduction: Given the high mortality rate within the ﬁrst year of dialysis initiation, an accurate estimation
of postdialysis mortality could help patients and clinicians in decision making about initiation of dialysis.
We aimed to use machine learning (ML) by incorporating complex information from electronic health
records to predict patients at risk for postdialysis short-term mortality.
Methods: This study was carried out on a contemporary cohort of 27,615 US veterans with incident end-stage
renal disease (ESRD). We implemented a random forest method on 49 variables obtained before dialysis
transition to predict outcomes of 30-, 90-, 180-, and 365-day all-cause mortality after dialysis initiation.
Results: The mean (SD) age of our cohort was 68.7  11.2 years, 98.1% of patients were men, 29.4% were
African American, and 71.4% were diabetic. The ﬁnal random forest model provided C-statistics (95%
conﬁdence intervals) of 0.7185 (0.6994–0.7377), 0.7446 (0.7346–0.7546), 0.7504 (0.7425–0.7583), and 0.7488
(0.7421–0.7554) for predicting risk of death within the 4 different time windows. The models showed good
internal validity and replicated well in patients with various demographic and clinical characteristics and
provided similar or better performance compared with other ML algorithms. Results may not be gener-
alizable to non-veterans. Use of predictors available in electronic medical records has limited the
assessment of number of predictors.
Conclusion: We implemented and ML-based method to accurately predict short-term postdialysis mor-
tality in patients with incident ESRD. Our models could aid patients and clinicians in better decision making
about the best course of action in patients approaching ESRD.
Kidney Int Rep (2019) 4, 1219–1229; https://doi.org/10.1016/j.ekir.2019.06.009
KEYWORDS: chronic kidney disease; dialysis; end-stage renal disease; mortality; random forest
Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).P atients with ESRD on dialysis represent a growinggroup characterized by extremely high morbidity
and mortality.1 Mortality is especially high in the ﬁrst
few months and up to a year after dialysis transition.1,2
Patients transitioning to dialysis are often acutely ill,
and suffer from major comorbid conditions that
portend a poor short-term survival,3 yet dialysis isspondence: Csaba P. Kovesdy, Nephrology Section,
his VA Medical Center, 1030 Jefferson Avenue, Memphis,
ssee 38104, USA. E-mail: ckovesdy@uthsc.edu
ved 13 February 2019; revised 30 April 2019; accepted 10
2019; published online 22 June 2019
International Reports (2019) 4, 1219–1229frequently initiated by health care providers without
considering short-term outcomes in their discussions
with patients and relatives.4 Better knowledge about
chances to survive in the immediate aftermath of
dialysis transition would allow patients to weigh their
desire to extend their life to a certain duration versus
their quality of life during this time, and more
informed patients may elect to pursue other modalities
such as conservative or palliative care as opposed to
aggressive and invasive interventions.
Several studies have attempted to create prediction
models that would allow the quantiﬁcation of post-
dialysis mortality to aid informed decision making at1219
CLINICAL RESEARCH O Akbilgic et al.: Predicting Mortality After Dialysis Initiationthe time of dialysis initiation.5–14 Most of these studies
used data from patients who have already started
dialysis,5–13 and hence their utility in aiding pre-
transition decisions about starting or deferring dialysis
is questionable. In addition, many of these studies had
other signiﬁcant limitations, such as limited sample
size,5,8,14 the use of restricted populations (e.g.,
elderly6,7,11,14), or a lack of information about data with
potentially important predictive potential, such as race/
ethnicity or various laboratory parameters.5–10,12–14
We recently developed a prediction model from a
large contemporary cohort of US veterans with incident
ESRD, using detailed patient information form the
pre-ESRD period, and showing improved diagnostic
performance in predicting short-term posttransition
mortality.15 In addition to improvement in population
size, composition, and available data, methodological
advances in prediction modeling also allow for
improvement in prediction parameters. Our aim was to
improve on the predictive characteristics of our pre-
vious model by implementing an ML algorithm using a
random forest method that allows the development of a
generalizable model and is also transparent and pro-
vides information about the importance of individual
variables included in the model.MATERIALS AND METHODS
Study Population and Patient Characteristics
We used data from a historic cohort of 85,505 US vet-
erans with incident ESRD (Transition of Care in Chronic
Kidney Disease, TC-CKD) who transitioned to dialysis
treatment between October 1, 2007, and March 31,
2014. The inclusion and exclusion criteria and the data
sources used for generating the analytical data set for
this study were previously described,15 and the cohort
selection is shown in Supplementary Figure S1. Brieﬂy,
we excluded patients with missing information on race/
ethnicity, on estimated glomerular ﬁltration rate (eGFR)
in the 12 months before ESRD transition, on the cause of
their ESRD, and on the diagnostic code for renal disease.
For each outcome, we further excluded 35, 64, 108, and
317 patients due to missing 30-, 90-, 180-, and 365-day
complete follow-up, respectively. A total of 49 patient
characteristics (including demographics, comorbidities,
vital signs, vital status, and laboratory characteristics)
were identiﬁed from a combination of US Renal Data
System, Centers for Medicare and Medicaid Services
databases and Department of Veterans Affairs admin-
istrative databases, as previously described.16,17 All
laboratory parameters (including eGFR) and vital signs
(systolic and diastolic blood pressure and body mass
index) were obtained before dialysis transition, and the
value recorded closest to transition was used for1220analyses. eGFR was estimated using the Chronic Kidney
Diseases Epidemiology Collaboration formula.18 We
further excluded 8263 patients (w23%) with missing
information on systolic and diastolic blood pressure and
blood sugar. The ﬁnal analytical cohort consisted of
27,615 patients with complete data for the 49 baseline
characteristics. We did not implement any trans-
formation or normalization for continuous predictor
variables. In a sensitivity analysis, we imputed missing
laboratory data and vital signs by using their mean
values. The outcome of interest was all-cause mortality
occurring within 30, 90, 180, and 365 days of tran-
sitioning to dialysis. Deaths were identiﬁed from
Department of Veterans Affairs Vital Status Files, which
have 98% sensitivity and speciﬁcity when compared
with the National Death Index.19
Predictive Modeling
In traditional Cox proportional hazard regression, the
outcome variable is the time to an event. In our approach,
we implemented a classiﬁcation task by treating the
outcome as a binary variable representing the occurrence
of the event, death in our case, within a certain predic-
tion window. We constructed 4 different prediction
models for mortality (corresponding to deaths within 30,
90, 180, and 365 days of dialysis transition) from survival
data up to 14 months following transition to dialysis. We
implemented ML with a random forest method as our
main predictive model to identify patients with ESRD at
high risk of death within the ﬁrst year of dialysis tran-
sition. Random forest is an iterative ML method that
ensembles multiple simple decision trees to provide the
ﬁnal outcome. At each iteration, a random subset of the
predictors is selected, and a decision tree is built using
selected predictors. By repeating this multiple times,
different simple decision trees are obtained and
embedded into the random forest framework.20 In our
models, predictors of mortality consisted of de-
mographics, laboratory results, and comorbid conditions.
We executed random forest models each inducing 500
decision trees for each outcome of interest by using 49
risk factors as predictors. We report predictive discrim-
ination as C-statistics. We compared the results from our
random forest method with logistic regression and to
other commonly used ML algorithms, such as artiﬁcial
neural networks (ANN), support vector machines, and k-
nearest neighborhood, by treating our outcome as a bi-
nary variable, and Cox proportional hazard regression
and random forest survival models by using an outcome
variable representing time from initiation of dialysis to
death. As a type of ML, ANN is a broad category of
methods that can be used for classiﬁcation, clustering,
and prediction. In this study, we implemented a super-
vised feed-forward multilayer network model. In aKidney International Reports (2019) 4, 1219–1229
O Akbilgic et al.: Predicting Mortality After Dialysis Initiation CLINICAL RESEARCHfeed-forward ANN model, the information (input or
predictors) is exposed to nonlinear transformation
through hidden layers and then connected to the
outcome (dependent variable) layer. Support vector
machines are supervised ML models that can be used
for binary classiﬁcation by ﬁnding the optimal hy-
perplane separating data coming from 2 distinct cat-
egories. Finally, k-nearest neighborhoods are
supervised, nonparametric, and instance-based algo-
rithms that memorize input-output associations from
training and then estimate the best outcome for a
given new input based on its similarity to input data
within the training set.
For model building and validation, we split our data
into training and testing based on geographical split-
ting.21 This layer of cross-validation is to address
possible geography-based overﬁtting. The number of
subjects within zip codes starting with 0 to 9 were 1794,
2711, 3374, 2853, 5400, 281, 829, 1909, 3871, 1840, and
2753, respectively. We selected cases with zip codes
starting with 0 to 8 for the training data and we built a
10-fold cross-validated (internal validation) model. This
layer of cross-validation was to address overﬁtting due to
random splitting of the data. We then implemented the
cross-validated model on the test set (external validation)
that consisted of cases from zip codes starting with 9. We
repeated this process 10 times by changing the test data
from zip codes 9 to 0 for all 4 prediction windows. In a
sensitivity analysis, we also split the data randomly in a
ratio of 80/20, corresponding to cohorts of 22,092 and
5523 patients for training and testing, respectively, and
repeated this process 100 times. Once the generalizability
of the random forest–based predictive models was veri-
ﬁed via both internal and external validation, we built
ﬁnal random forest models using the entire data set with
10-fold cross-validation. We examined the C-statistics
from the ﬁnal models both overall and in relevant sub-
groups of patients to determine consistency of the re-
sults. To assess how well the predicted probabilities
reﬂect the actual survival rate, we split all predicted
probability values from ﬁnal models into 5 clusters based
on increasing intervals of predicted risk: 0 to <5th, 5th
to <35th, 35th to <65th, 65th to <95th, and 95th
to #100th percentiles. We annotated subjects within
these 5 categories as “Low Risk,” “Mid-Low Risk,” “Mid
Risk,” “Mid-High Risk,” and “High Risk,” respectively.
For each risk group and for each prediction window, we
calculated the survival rate and compared it graphically
with the observed survival rate. We also used indepen-
dent sample t and Mann-Whitney U tests to compare
predicted risk of death between groups of patients who
died and those who survived.
Using the ﬁnal models, we implemented a variable
importance analysis to identify which speciﬁcKidney International Reports (2019) 4, 1219–1229predictors are the main predictors of mortality (Figure
1). The variable importance analysis was based on the
mean decrease in accuracy by exclusion of a speciﬁc
variable. To do so, each variable was dropped from the
ﬁnal model and the performance of the new model was
compared with the original model. Predictors causing a
large decrease in accuracy when dropped are consid-
ered more important than the variables causing less
decrease in accuracy when dropped from the model.
We normalized the variable importance to (0–100) in-
tervals, where 0 represents the minimum importance
(lowest decrease in the accuracy when excluded) and
100 represents the maximum importance (highest
decrease in the accuracy when excluded).
To obtain simpler predictive models, we carried out
another simulation study based on the variable
importance ranking for 30-day mortality variables. In
this simulation study, we built 49 different random
forest models with 10-fold cross-validation by intro-
ducing new risk factors into the model step-by-step
based on their importance. First, we built a model
using the variable found to be the most important
predictor. Second, we used the ﬁrst and second most
important variable, third, the ﬁrst 3 most important
variables, and so on. Finally, the last model was built
using all predictors, and the 10-fold cross-validated
area under the curve (AUC) corresponding to each of
the 49 models is shown graphically in Figure 2, to
indicate the point where the introduction of additional
variables does not result in substantial further increase
in AUC.
To make our approach more applicable in clinical
practice, we proceeded to building predictive models
using a smaller number of variables without loss of
predictive performance. To do that, we ranked the
risk factors based on their importance and built new
models by introducing new risk factors step-by-step
into the model. We built separate 10-fold cross-
validated models for each prediction window (i) by
using the risk factors that provided at least 0.001
increment in AUC when they were introduced into
the model, (ii) by retaining only the top 15 most
important predictor variables (since the increment in
AUC stabilized for each prediction window by
addition of the 15th most important predictor), and
(iii) by applying a combination of these 2 approaches.
Because the accuracies of the models were comparable
for these 3 approaches (data not shown), and because
the same top 15 variables ended up being used for all
prediction windows, we applied the approach using
the 15 top predictor variables and built ﬁnal compact
models using the entire data set. The R-code of our
model is available on request for interested
researchers.1221
Figure 1. Variable importance analysis. Results indicate the decrease in accuracy of the ﬁnal model on exclusion of each speciﬁc variable,
quantiﬁed on a relative scale of 0 to 100, where 0 represents the minimum importance (lowest decrease in the accuracy when excluded) and
100 represents the maximum importance (highest decrease in the accuracy when excluded). alb, serum albumin; alkphos, serum alkaline
phosphatase; bmi, body mass index; bun, blood urea nitrogen; cci-1, myocardial infarction; cci-2, congestive heart failure; cci-3, peripheral
vascular disease; cci-4, cerebrovascular disease; cci-5, dementia; cci-6, chronic pulmonary disease; cci-7, connective tissue disease/rheumatic
disease; cci-8, peptic ulcer disease; cci-9, mild liver disease; cci-10, diabetes without complications; cci-11, diabetes with complications; cci-12,
paraplegia/hemiplegia; cci-13, renal disease; cci-14, nonmetastatic cancer; cci-15, moderate or severe liver disease; cci-16, metastatic car-
cinoma; cci-17, HIV/AIDS; cESRD-1, diabetes; cESRD-2, hypertension/large-vessel disease; cESRD-3, primary glomerulonephritis; cESRD-4,
interstitial nephritis/pyelonephritis; cESRD-5, neoplasm/tumors; cESRD-6, cystic/hereditary/congenital diseases; cESRD-7, secondary glomer-
ulonephritis; cESRD-8, miscellaneous conditions; chr-1, anemia; chr-2, atrial ﬁbrillation; chr-3, depression; chr-4, hyperlipidemia; chr-5, hy-
pertension; chr-6, ischemic heart disease; DBP, diastolic blood pressure; D30, 30-day mortality; D90, 90-day mortality; D180, 180-day mortality;
D365, 365-day mortality; glu, blood glucose; na, serum sodium; Native A, Native American; SBP, systolic blood pressure; wbc, white blood cell
count.
CLINICAL RESEARCH O Akbilgic et al.: Predicting Mortality After Dialysis InitiationThe study was approved by the institutional re-
view boards of the Memphis and Long Beach Veter-
ans Affairs Medical Centers, with waiver of written
informed consent. All analyses were performed on R1222version 3.4.1 using “randomForest,”22 “class,”23
“e1071,”24 “neuralnet,”25 and “ggrandomFor-
estSRC”26 for various ML algorithms, and ﬁgures
were generated using MATLAB (MathWorks, Natick,Kidney International Reports (2019) 4, 1219–1229
Figure 2. Incremental change in 10-fold cross-validated area under the curve (AUC) on entering individual variables one by one into the
predictive model. Variables were entered in the order established by the variable importance analysis for 30-day mortality (Figure 1) as long as
they increased the AUC by at least 0.001. alb, serum albumin; alkphos, serum alkaline phosphatase; bmi, body mass index; bun, blood urea
nitrogen; cci-1, myocardial infarction; cci-2, congestive heart failure; cci-3, peripheral vascular disease; cci-4, cerebrovascular disease; cci-5,
dementia; cci-6, chronic pulmonary disease; cci-7, connective tissue disease/rheumatic disease; cci-8, peptic ulcer disease; cci-9, mild liver
disease; cci-10, diabetes without complications; cci-11, diabetes with complications; cci-12, paraplegia/hemiplegia; cci-13, renal disease; cci-14,
nonmetastatic cancer; cci-15, moderate or severe liver disease; cci-16, metastatic carcinoma; cci-17, HIV/AIDS; cESRD-1, diabetes; cESRD-2,
hypertension/large-vessel disease; cESRD-3, primary glomerulonephritis; cESRD-4, interstitial nephritis/pyelonephritis; cESRD-5, neoplasm/tu-
mors; cESRD-6, cystic/hereditary/congenital diseases; cESRD-7, secondary glomerulonephritis; cESRD-8, miscellaneous conditions; chr-1,
anemia; chr-2, atrial fibrillation; chr-3, depression; chr-4, hyperlipidemia; chr-5, hypertension; chr-6, ischemic heart disease; DBP, diastolic
blood pressure; D30, 30-day mortality; D90, 90-day mortality; D180, 180-day mortality; D365, 365-day mortality; glu, blood glucose; na, serum
sodium; Native A, Native American; SBP, systolic blood pressure; wbc, white blood cell count.
O Akbilgic et al.: Predicting Mortality After Dialysis Initiation CLINICAL RESEARCHMA) version 2018a and IBM SPSS Statistics version
25 (Armonk, NY).RESULTS
Table 1 shows baseline characteristics of the 27,615 pa-
tients included in the ﬁnal cohort. Mean (SD) age was
68.7  11.2 years, 98.1% of patients were men, 29.4%
were African American, and 71.4% were diabetic.Kidney International Reports (2019) 4, 1219–1229Table 2 summarizes the average C-statistics with
95% conﬁdence intervals (CIs) of the random forest
model using all 49 baseline characteristics as predictors
in the training (internal validation: these are 10-fold
cross-validation results over training data) and testing
sets (external validation) deﬁned based on the zip codes
of the individual patients’ home residence address.
Results were similar with sensitivity analysis, whereas
the training and testing sets were based on random1223
Table 1. Baseline characteristics (N ¼ 27,615)
Age, yr 68.7  11.2
Male sex 27,101 (98.1)
Race
White 18,162 (65.8)
Black 8127 (29.4)
Native American 182 (0.7)
Asian 150 (0.5)
Other 994 (3.6)
Hispanic ethnicity 2119 (7.7)
Cause of ESRD
Diabetes 13,414 (48.6)
Hypertension/large-vessel disease 8113 (29.4)
Primary glomerulonephritis 1396 (5.1)
Interstitial nephritis/pyelonephritis 713 (2.6)
Neoplasm/tumors 689 (2.5)
Cystic/hereditary/congenital diseases 454 (1.7)
Secondary glomerulonephritis 243 (0.9)
Miscellaneous conditions 2591 (9.4)
Comorbidities
Myocardial infarction 6884 (24.8)
Congestive heart failure 14,895 (53.9)
Peripheral vascular disease 10,179 (36.9)
Cerebrovascular disease 8259 (29.9)
Dementia 609 (2.2)
Chronic pulmonary disease 11,143 (40.4)
Connective tissue disease/rheumatic disease 1008 (3.7)
Peptic ulcer disease 1747 (6.3)
Mild liver disease 2514 (9.1)
Diabetes without complications 4982 (18.0)
Diabetes with complications 14,754 (53.4)
Paraplegia/hemiplegia 844 (3.1)
Renal disease 27,615 (100)
Nonmetastatic cancer 5635 (20.4)
Moderate or severe liver disease 616 (2.2)
Metastatic carcinoma 610 (2.2)
HIV/AIDS 315 (1.1)
Anemia 20,272 (73.4)
Atrial ﬁbrillation 4196 (15.2)
Depression 7210 (26.1)
Hyperlipidemia 22,432 (81.2)
Hypertension 27,105 (98.2)
Ischemic heart disease 15,780 (57.1)
Body mass index (kg/m2) 29.9  6.7
Vital signs
Systolic blood pressure (mm Hg) 140.3  23.2
Diastolic blood pressure (mm Hg) 72.5  13.7
Laboratory characteristics
Last eGFR (ml/min per 1.73 m2) 11.7 (8.3–17.3)
White blood cells (103/ml) 7.8  3.5
Serum sodium (mEq/l) 138.9  3.8
Serum albumin (g/dl) 3.4  0.7
Serum urea nitrogen (mg/dl) 66.9  29.3
Serum alkaline phosphatase (IU/l) 96.3  71.8
Glucose (mg/dl) 129.6  59.0
eGFR, estimated glomerular ﬁltration rate; ESRD, end-stage renal disease.
Values are provided as means  SD, median (25th–75th percentile), and number (%).
CLINICAL RESEARCH O Akbilgic et al.: Predicting Mortality After Dialysis Initiationsplits of 80%/20% (Supplementary Table S1). All the
C-statistics were similar in the training and testing sets,
indicating that the random forest models were gener-
alizable within the Veteran Affairs cohort for all 41224outcomes of interest. The ﬁnal model for each outcome
using the entire US veteran dataset showed C-statistics
(95% CI) of 0.718 (0.708–0.718), 0.758 (0.749–0.766),
0.762 (0.754–0.770), and 0.760 (0.751–0.769) for 30-day,
90-day, 180-day, and 365-day mortality, respectively.
Figure 1 shows results from the variable importance
analysis using the ﬁnal cross-validated models for the 4
outcomes. eGFR, systolic blood pressure, and age were
consistently the 3 most important predictors of
outcome for each prediction window. Other variables
that were important for prediction in the different
models were diastolic blood pressure, blood urea ni-
trogen, body mass index, serum alkaline phosphatase,
congestive heart failure, and chronic pulmonary dis-
ease. Figure 2 shows the contribution of the individual
patient characteristics to the 10-fold cross-validated
AUC of the predictive model when entered one by
one into the model. The AUC showed no substantial
increase after the addition of the 15th most important
predictor. The C-statistic and 95% CI for the simpliﬁed
model that included the top 15 predictive variables
were 0.719 (0.699–0.738), 0.745 (0.735–0.755), 0.750
(0.743–0.758), and 0.749 (0.742–0.755) for the 30-day,
90-day, 180-day, and 365-day mortality outcomes,
respectively, with Figure 3 showing the corresponding
receiver operating characteristic curves. Table 3 shows
the C-statistics and 95% CIs of the ﬁnal compact pre-
dictive model in select subgroups of patients, indi-
cating consistent results in all subgroups, except for a
better predictive performance in patients whose pre-
transition eGFR was <15 ml/min per 1.73 m2 compared
with those with eGFR $15 ml/min per 1.73 m2.
Supplementary Figures S2 and S3 and Supplementary
Table S2 show the comparison of predicted and
observed all-cause mortality, indicating consistent re-
sults when categorizing patients by quartiles of pre-
dicted mortality rate from low risk to high risk
(Supplementary Figure S2) and when comparing pre-
dicted mortality rates between patients who survived
and those who died (Supplementary Figure S3 and
Supplementary Table S2).
For comparison, we implemented ANN, support
vector machines, k-nearest neighborhood, and logis-
tic regression methods to predict risk for death within
1 year of initiation of dialysis by implementing the
same geographic location–based cross-validation
protocol. The multilayer ANN architecture with a
single hidden layer including 100 neurons and using
an activation function of sigmoid provided C-statis-
tics (95% CI) of 0.606 (0.561–0.645). A support vector
machines model provided C-statistics (95% CI) of
0.719 (0.708–0.730). When we implemented a k-
nearest neighborhood algorithm with k ¼ 10, it pro-
vided C-statistics (95% CI) of 0.654 (0.642–0.666),Kidney International Reports (2019) 4, 1219–1229
Table 2. Predictive model performance in cross-validated models split by geographic location
C-statistics with 95% conﬁdence interval
30-day mortality 90-day mortality 180-day mortality 365-day mortality
Training 0.7179 (0.7144–0.7214) 0.7594 (0.7578–0.7611) 0.7628 (0.7606–0.7649) 0.7596 (0.7582–0.7610)
Test 0.7361 (0.7149–0.7573) 0.7637 (0.7535–0.7739) 0.7604 (0.747458–0.7751) 0.7574 (0.7463–0.7686)
The initial training set was deﬁned based on individual patient residence zip codes starting with 0 to 8 and the test set was deﬁned based on zip codes starting with 9. We repeated this
process 10 times by changing the test data zip codes from 9 to 0 for all for prediction windows. The values presented are the average C-statistics from all models.
O Akbilgic et al.: Predicting Mortality After Dialysis Initiation CLINICAL RESEARCHwhile logistic regression providing C-statistics (95%
CI) of 0.682 (0.649–0.714). Our random forest survival
analysis using an outcome variable representing the
time to death from initiation of dialysis including 200
individual trees provided C-statistics (95% CI) of
0.688 (0.656–0.710). We also ran Cox regression and
obtained C-statistics (95% CI) of 0.714 (0.706–0.722).
Supplementary Figure S4 shows comparisons of all
models considered.D30
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Figure 3. Receiver operator curves of the ﬁnal compact predictivemodel based
AUC, area under the curve; CI, conﬁdence interval; D30, 30-day mortality; D90
Kidney International Reports (2019) 4, 1219–1229The results were similar when using a patient cohort
of 35,878 patients with imputed values for missing
laboratory data and vital signs (C-statistic and 95% CI
for 1-year mortality: 0.749 [0.744–0.755]).DISCUSSION
We developed a new risk score to predict postdialysis
all-cause mortality in patients with incident ESRDD90
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on the top 15 predictors of 30-day, 90-day, 180-day, and 365-daymortality.
, 90-day mortality; D180, 180-day mortality; D365, 365-day mortality.
1225
Table 3. C-statistics and 95% conﬁdence intervals in select subgroups of patients
D30 D90 D180 D365
n AUC n AUC n AUC n AUC
Overall 27,580 0.719 (0.699, 0.738) 27,551 0.745 (0.735, 0.755) 27,507 0.750 (0.743, 0.758) 27,298 0.749 (0.742, 0.755)
Age
<65 11,306 0.696 (0.648, 0.743) 11,298 0.727 (0.704, 0.750) 11,291 0.731 (0.714, 0.748) 11,227 0.730 (0.717, 0.743)
$65 16,274 0.689 (0.667, 0.711) 16,253 0.710 (0.698, 0.722) 16,216 0.717 (0.708, 0.727) 16,071 0.717 (0.709, 0.725)
Race
Black 8,119 0.716 (0.666, 0.766) 8108 0.768 (0.746, 0.791) 8098 0.771 (0.754, 0.789) 8051 0.756 (0.742, 0.771)
White 18,136 0.698 (0.677, 0.720) 18,119 0.721 (0.709, 0.733) 18,087 0.726 (0.717, 0.736) 17,932 0.725 (0.717, 0.733)
Sex
Female 514 0.701 (0.550, 0.852) 513 0.701 (0.614, 0.787) 513 0.752 (0.682, 0.822) 505 0.753 (0.693, 0.812)
Male 27,066 0.719 (0.699, 0.738) 27,038 0.745 (0.735, 0.755) 26,994 0.750 (0.742, 0.758) 26,793 0.748 (0.741, 0.755)
Type of dialysis
Hemodialysis 25,976 0.713 (0.694, 0.733) 25,949 0.740 (0.730, 0.750) 25,908 0.745 (0.737, 0.754) 25,709 0.744 (0.738, 0.751)
Peritoneal dialysis 1363 0.790 (0.654, 0.925) 1361 0.777 (0.706, 0.848) 1358 0.794 (0.742, 0.845) 1352 0.767 (0.727, 0.808)
Cause of ESRD
Diabetes
Yes 13,399 0.700 (0.667, 0.734) 13,388 0.730 (0.713, 0.747) 13,375 0.735 (0.722, 0.748) 13,285 0.738 (0.728, 0.748)
No 14,181 0.719 (0.695, 0.742) 14,163 0.742 (0.730, 0.755) 14,132 0.751 (0.741, 0.761) 14,013 0.750 (0.741, 0.758)
Hypertension
Yes 8099 0.707 (0.676, 0.738) 8089 0.742 (0.725, 0.759) 8069 0.752 (0.738, 0.766) 7992 0.748 (0.737, 0.760)
No 19,481 0.721 (0.697–0.745) 19,462 0.743 (0.731–0.756) 190,438 0.748 (0.738–0.758) 19,306 0.747 (0.739, 0.756)
Comorbidities
Congestive heart failure
Yes 14,876 0.683 (0.660–0.706) 14,862 0.716 (0.703–0.729) 14,840 0.725 (0.715–0.735) 14,713 0.725 (0.717, 0.734)
No 12,704 0.729 (0.690–0.767) 12,689 0.746 (0.727–0.764) 12,667 0.746 (0.731–0.760) 12,585 0.734 (0.722, 0.745)
Chronic pulmonary disease
Yes 11,133 0.678 (0.651–0.705) 11,119 0.700 (0.686–0.715) 11,102 0.710 (0.698–0.722) 11,000 0.716 (0.706, 0.726)
No 16,447 0.731 (0.702–0.760) 16,432 0.754 (0.739–0.769) 16,405 0.753 (0.741–0.765) 16,298 0.745 (0.735, 0.754)
eGFR
<15 18,528 0.720 (0.690, 0.751) 18,512 0.733 (0.717–0.749) 18,489 0.737 (0.725–0.748) 18,386 0.728 (0.719–0.738)
$15 9052 0.643 (0.615, 0.671) 9039 0.675 (0.660–0.690) 9018 0.686 (0.674–0.699) 8912 0.699 (0.688–0.710)
AUC, area under the curve; D, day; ESRD, end-stage renal disease.
Results represent C-statistics and 95% conﬁdence intervals based on the ﬁnal compact predictive model including the 15 most important variables.
CLINICAL RESEARCH O Akbilgic et al.: Predicting Mortality After Dialysis Initiationusing exclusively information available before dialysis
transition in a large national cohort of US veterans. Our
random forest–based predictive model showed good
validity when tested in cohorts divided geographically
and discriminated well in various subgroups. Our
model also provided similar or better performance in
terms of C-statistic when compared with methods such
as ANN, logistic regression, support vector machines,
k-nearest neighborhood, Cox regression, and random
forest survival. However, we have not compared our
results with more novel survival approaches such as
Deep Survival Analysis27,28 because of computational
limitations within our systems.
Interestingly, our 1-year mortality prediction was
better than the 30-days mortality prediction. This
may be because all-cause mortality may be a result
of different causes of death at different time points,
and the covariates included in our models may be
better at predicting the types of deaths occurring at
1 year.
The predictive performance of our model (C-statis-
tics with 95% CI of 0.76; 0.75–0.77) were superior to1226the performance of more traditionally used Cox
regression models (C-statistics with 95% CI of 0.714;
0.706–0.722). This may be due to the distribution- and
assumption-free nature of the random forest model
allowing simultaneous use of predictors with high
correlation. We also note that the performance of the
current Cox regression model was slightly better than
the performance of the Cox regression model (0.71;
0.70–0.72 for eGFR <15 and 0.66; 0.65–0.67 for eGFR
$15) previously built on the same cohort.15 This may
be because of our inclusion of additional predictors
(blood pressure and blood glucose) in our current
model. Two other major studies examined 6-month
postdialysis all-cause mortality, both implementing a
logistic regression model.7,11 In terms of AUC com-
parison for 6-month postdialysis mortality prediction,
the C-statistic of 0.76 we obtained was higher
compared with the C-statistic of 0.69 in the study by
Thamer et al.11 and 0.70 in the study by Couchoud
et al.7 Besides differences in the applied prediction
methods, differences from these studies also could be
explained by differences in the studied patientKidney International Reports (2019) 4, 1219–1229
O Akbilgic et al.: Predicting Mortality After Dialysis Initiation CLINICAL RESEARCHpopulation and differences in the available predictor
variables.
ESRD is a complex disease state, with complex in-
teractions among demographic, comorbid, and labora-
tory characteristics. As opposed to traditional methods,
the ML-based random forest method used by us to
develop our prediction model is ideally suited to
incorporate complex interactions between numerous
outcome predictors, and hence could result in superior
predictive performance. Two main critiques of ML-
based predictive models in clinical decision making
are that they are not intuitive (they are often referred to
as “black box” methods), and that they may result in
overﬁtting causing limited generalizability. In our
study, we used the random forest method as the main
predictive model algorithm because (i) it is suitable for
variable importance analysis providing information on
which speciﬁc risk factors contribute more to the
outcome,20,29,30 and (ii) it usually provides more
generalizable models compared with other ML algo-
rithms.31–33
Our models are based on predialysis patient char-
acteristics, and hence they may aid decision making
before the initiation of dialytic therapies by informing
patients, caregivers, and health care providers about
the likely short-term risk of mortality if a patient were
to choose such a path. The knowledge of a numeric
risk could make it easier for patients to decide be-
tween a dialytic modality and more conservative in-
terventions, such as medications-only, or palliative
therapy, and could result in better patient-centered
outcomes such as quality of life for individuals with
high short-term mortality risk, and also in health care
savings.4,7 The application by clinicians of our model
or other similar models to predict future mortality and
to advise patients and families about outcomes will
need to be done with proper recognition of the
remaining limitations of such models. Notwithstanding
the moderate accuracy of currently available predic-
tion models, the ability to present a numerical risk of
death still represents an advance that could aid in the
discussion between caregivers and patients and family
members.
We used data that are available in electronic medical
records to develop our predictive models, which makes
system-wide scaling and automation of our method
possible in health care systems using computerized
patient records. Although the use of data from elec-
tronic medical records is an advantage from the
standpoint of scalability and generalizability across
systems, it also represents a limitation due to the lack of
patient characteristics that are not available in elec-
tronic medical records, such as various socioeconomic
and clinical characteristics known to have an importantKidney International Reports (2019) 4, 1219–1229role in ESRD (e.g., severity of various disease states,
nutritional status). The incorporation of such addi-
tional characteristics in future studies promises to
further improve our ability to predict mortality in this
population.
Our study has limitations that need to be recog-
nized when interpreting its ﬁndings. We used a
nationwide US veteran cohort to develop our predic-
tive models, which consisted of mostly male patients
with incident ESRD who all transitioned to dialysis.
Therefore, our model may not be applicable to female
patients or to patients at earlier stages of chronic
kidney disease, although previously a different pre-
dictive model using the same veteran population
validated well in an independent cohort with equal
representation of women.15 We used predictors
available in electronic medical records, which limited
the assessment of predictors; for example, the use of
International Classiﬁcation of Diseases codes for the
assessment of comorbid conditions can have low
sensitivity and does not allow for the determination of
stages of severity for most of them, and certain con-
ditions cannot be characterized at all. Furthermore, we
excluded a large proportion of the source cohort due
to missing data, which could limit our ability to
extend conclusions to the entire US veteran popula-
tion. Another limitation is exclusion of several vari-
ables that have been shown to predict outcomes in
dialysis patients, such as vascular access at the time of
dialysis transition,34 the use of certain medications35
or the length of care received in the predialysis
period,36 proteinuria,37 serum phosphorus,38 or hepa-
titis C seropositivity.39 Our exclusion of these variables
was motivated by a desire to use solely patient charac-
teristics assessed before reaching a decision about renal
replacement therapy, and those that are not primarily
representative of health care system or practitioner
behavior. Other variables such as laboratory tests with
known predictive ability (e.g., proteinuria, serum
phosphorus, or hepatitis C seropositivity) were excluded
due to high degrees of combined missingness in our
cohort. Incorporation of this and other clinical infor-
mation has the potential to further improve predictive
performance, which can be tested in future studies.
Finally, although our results were internally valid, we
did not have access to an independent data set to
perform external validation of our results. We will
therefore provide our R-code to researchers who intend
to test our approach on their own data.
To conclude, we used ML methods to predict short-
term all-cause mortality in incident dialysis patients
based on predialysis information alone. Our models
could help informing patients and caregivers about
short-term postdialysis mortality and may aid decision1227
CLINICAL RESEARCH O Akbilgic et al.: Predicting Mortality After Dialysis Initiationmaking in patients who are faced with ESRD. Our
online risk calculator will also allow the immediate
application of our risk scores in clinical practice.DISCLOSURE
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